These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36093917)

  • 21. Activation Syndrome in a Patient With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine: A Case Report.
    Karakaya SEK; Yektaş Ç; Tufan AE
    Clin Neuropharmacol; 2021 May-Jun 01; 44(3):101-103. PubMed ID: 33661138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Autism and ADHD across the life span. Differential diagnoses or comorbidity?].
    Banaschewski T; Poustka L; Holtmann M
    Nervenarzt; 2011 May; 82(5):573-80. PubMed ID: 21484168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent.
    Baytunca MB; Kose S; Ozbaran B; Erermis S
    Pediatr Int; 2016 Jan; 58(1):61-3. PubMed ID: 26542690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Severe Adverse Effect of Atomoxetine: Hypertensive Crisis.
    Guldiken G; Karayagmurlu A
    Clin Neuropharmacol; 2020; 43(2):50-51. PubMed ID: 32106139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
    Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
    Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternations in nuclear factor kappa beta activity (NF-kB) in the rat brain due to long-term use of atomoxetine for treating ADHD: In vivo and in silico studies.
    Gür F; Cengiz M; Gür B
    Biochem Biophys Res Commun; 2021 Jan; 534():927-932. PubMed ID: 33143874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
    Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
    CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
    Walker DJ; Mason O; Clemow DB; Day KA
    Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder.
    Upadhyaya H; Kratochvil C; Ghuman J; Camporeale A; Lipsius S; D'Souza D; Tanaka Y
    J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):799-809. PubMed ID: 25265343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder.
    Harfterkamp M; van der Meer D; van der Loo-Neus G; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2015 May; 25(4):372-5. PubMed ID: 25919900
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature.
    Joshi G; Wilens T; Firmin ES; Hoskova B; Biederman J
    J Psychopharmacol; 2021 Mar; 35(3):203-210. PubMed ID: 33349107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caregiver Satisfaction with a Multisite Trial of Atomoxetine and Parent Training for Attention-Deficit/Hyperactivity Disorder and Behavioral Noncompliance in Children with Autism Spectrum Disorder.
    Hollway JA; Aman MG; Mendoza-Burcham MI; Silverman L; Arnold LE; Tumuluru R; Handen BL; Lecavalier L; Page K; Sayre P; Smith T
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):807-814. PubMed ID: 26797318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder.
    Houghton R; de Vries F; Loss G
    CNS Drugs; 2020 Jan; 34(1):93-101. PubMed ID: 31768949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
    Anagnostou E
    Curr Opin Neurol; 2018 Apr; 31(2):119-125. PubMed ID: 29389748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
    Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.
    Lamberti M; Siracusano R; Italiano D; Alosi N; Cucinotta F; Di Rosa G; Germanò E; Spina E; Gagliano A
    Paediatr Drugs; 2016 Aug; 18(4):319-29. PubMed ID: 27278054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.